Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Capadenoson · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Capadenoson (BAY68-4986) | DRUG | 4 mg BAY68-4986 for five days |
Inclusion Criteria: * Male and/or female (without childbearing potential) white patients * History of persistent or permanent atrial fibrillation * 18 to 75 years of age Exclusion Criteria: * Patients with high-risk cardiovascular diseases * Stroke or myocardial infarction * Relevant pathological...
Capadenoson is an investigational small molecule being studied for the treatment of atrial fibrillation, specifically to investigate its effect on ventricular heart rate in patients with persistent or permanent atrial fibrillation. It is a cardiovascular therapeutic agent developed by Bayer AG.
Capadenoson is an A1 adenosine receptor agonist. It works by activating the A1 receptor, which is involved in regulating heart rate. This mechanism is being studied to determine its effect on ventricular heart rate in patients with persistent or permanent atrial fibrillation.
Capadenoson is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market.
Capadenoson is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an uncontrolled, non-randomized, open-label study. The drug is still investigational and has not been approved by regulatory authorities.
Capadenoson has one completed clinical trial, identified as NCT00568945. This Phase 2 study investigated the effect of the A1 agonist Capadenoson on ventricular heart rate in patients with persistent or permanent atrial fibrillation. The trial was conducted in Germany and enrolled 28 participants.